The company will establish a new laboratory in Uppsala, Sweden, during the spring.
The lab will be well-equipped for vaccine development, with instrumentation that enables the company to develop more vaccine candidates in a faster and more cost-effective manner, states the company.
“Abera’s operations have evolved significantly in recent years, transitioning from discovery research to product development, which imposes different requirements on equipment and expertise. In the new lab, we will have the opportunity for broader development through enhanced analytical capacity and the ability to internally produce both bacterial and viral antigens for various vaccine candidates. This is a cornerstone of our quick-response initiative, where we strengthen our internal capacity, thereby increasing opportunities for further collaborations in the vaccine field,” says Mats Lundgren, CSO at Abera.
“With our own lab, we increase our flexibility and shorten the time for developing new vaccine prototypes. Additionally, it creates the opportunity to expand the company in the future. The funding for this initiative is cost-effective and is largely covered by the award received for pandemic preparedness, financed by Innovate UK, along with costs that we have already budgeted and covered. Two of our employees from the lab in Amsterdam will relocate to Sweden, and we will further strengthen the team going forward,” says Maria Alriksson, CEO of Abera Bioscience.
Photo of Maria Alriksson: Abera
